Press
releases

New Published Data Point to Spike Protein Interactions with Estrogen Receptors as a cause for Coagulopathy in Covid-19 Patients, Signaling Sex Effects and a Path to Improved Vaccines

December 5, 2022

Two Clinical Studies to Treat Mild-to-Moderate COVID-19 at Home Reveal Value of Exscalate, Dompé’s AI Platform for Drug Design

July 26, 2022

Dompé Announces Results of Phase 2 Study Evaluating the Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia

June 13, 2022

Dompé Further Elevates Commitment to Ophthalmics with Industry-Leading Hires

April 26, 2022

Dompé Further Elevates Commitment to Ophthalmics with Industry-Leading Hires

April 20, 2022

Dompé announces first patient enrolled in Phase 3 trial of cenegermin in patients with severe Sjögren's-related dry eye disease

February 10, 2022

Dompé announces first patient enrolled in Phase 3 trial of cenegermin in patients with severe Sjögren's-related dry eye disease

February 10, 2022

Dompé Farmaceutici S.P.A Announces Strategic Investment and Collaboration with Engitix Positioned Around Use of Dompé’s Exscalate Drug Discovery Platform

January 19, 2022

Dompé-Substipharm agreement for the sale of 6 brands

November 22, 2021

Dompé Announces Activation of U.S. Clinical Trial Sites for Phase 3 Study of Reparixin, an Oral Investigational CXCR1/CXCR2 Inhibitor, in Hospitalized Patients with Severe COVID-19 Pneumonia

June 3, 2021